Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Development of a Phenotypically Accurate in vitro Model of Diabetic Cardiomyopathy: A High-Throughput Approach

EF 2017-18

Résumé
Type 2 diabetes mellitus (T2D) is a chronic metabolic disease that is projected to affect 4 million Canadians (10% of population) and cost Canadians $15 billion annually by 2030. The leading cause of death among the T2D population is cardiovascular disease, accounting for ~50% of all diabetic deaths. Diabetic cardiomyopathy (DC) describes the enlargement and subsequent failure of the heart that is independent of coronary artery disease and hypertension; diabetes-specific metabolic changes within the contractile cells of the heart, cardiomyocytes (CMs), is central to DC pathogenesis. Unlike normal adult CMs which retain fuel plasticity under stress, DC CMs lose fuel plasticity and are reliant on only fatty acids. The loss of plasticity is linked to high plasma fatty acids in diabetics that alter cellular insulin signaling. This metabolic phenotype has been observed in both humans and rodents, but no engineered cell culture model properly demonstrates this unique DC phenotype. I propose the development of a DC model by first maturing human CM stem cells with a fatty acid-rich, glucose-low culture media until an adult CM metabolic phenotype is reached. Next the use of a culture media that is clinically-representative of diabetic blood plasma will mediate DC pathogenesis. Disease phenotype would be verified by measuring cellular metabolic plasticity and other disease markers. Once optimized this model would be transitioned into a high-throughput system previously developed in my lab, allowing for the rapid assessment of therapeutics. Ultimately, the model would allow for an in-depth study of DC pathogenesis and treatment without the disadvantages of ethical concerns, skilled manpower, long study periods, and high cost of animal models.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
386498
Name
Williams Kenneth
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a Phenotypically Accurate in vitro Model of Diabetic Cardiomyopathy: A High-Throughput Approach
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiomyocyte Maturation; Diabetes Mellitus; Diabetic Cardiomyopathy; Fatty Acids; Heart; Heart Failure; Hipsc; Insulin Resistance; Mitochondrial Biogenesis; Mitochondrial Dysfunction
Abstract
Type 2 diabetes mellitus (T2D) is a chronic metabolic disease that is projected to affect 4 million Canadians (10% of population) and cost Canadians $15 billion annually by 2030. The leading cause of death among the T2D population is cardiovascular disease, accounting for ~50% of all diabetic deaths. Diabetic cardiomyopathy (DC) describes the enlargement and subsequent failure of the heart that is independent of coronary artery disease and hypertension; diabetes-specific metabolic changes within the contractile cells of the heart, cardiomyocytes (CMs), is central to DC pathogenesis. Unlike normal adult CMs which retain fuel plasticity under stress, DC CMs lose fuel plasticity and are reliant on only fatty acids. The loss of plasticity is linked to high plasma fatty acids in diabetics that alter cellular insulin signaling. This metabolic phenotype has been observed in both humans and rodents, but no engineered cell culture model properly demonstrates this unique DC phenotype. I propose the development of a DC model by first maturing human CM stem cells with a fatty acid-rich, glucose-low culture media until an adult CM metabolic phenotype is reached. Next the use of a culture media that is clinically-representative of diabetic blood plasma will mediate DC pathogenesis. Disease phenotype would be verified by measuring cellular metabolic plasticity and other disease markers. Once optimized this model would be transitioned into a high-throughput system previously developed in my lab, allowing for the rapid assessment of therapeutics. Ultimately, the model would allow for an in-depth study of DC pathogenesis and treatment without the disadvantages of ethical concerns, skilled manpower, long study periods, and high cost of animal models.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Williams, Kenneth
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~